The Manila Times

AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug S…

Company to participate in Live Virtual Investor Closing Bell segment today, April 16th at 4:00 PM ET; Register for the ...

FDA seeks more power over drug ads, advisory panels

The Trump administration dropped its fiscal 2027 budget request Friday, and the massive document release includes some ...

AIM ImmunoTech Inc.: AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen in Pancreatic Cancer, Backed by Positive Clinical Signals ...

Company to participate in Live Virtual Investor Closing Bell segment today, April 16th?at?4:00 PM ET- Register for the event here OCALA, Fla., April 16, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (N ...

Inside NASA's audacious plan to build a nuclear-powered moon base

The end of the historic Artemis II mission kicks off a race to establish a permanent human presence on the moon.
Euronext Markets Live

Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria. Approval in CSU for children two to ...
DawgNation

Georgia powering through donor fatigue, raises $300 million-plus in NIL era

The collegiate sports landscape has led athletic departments to lean on donors and fundraise more than ever, but UGA ...

NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia

Alignment with the FDA across proposed study parameters of RESTORE, a 16-week registrational study evaluating NVG-291 in chronic ...

Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update

NORCROSS, Ga., March 31, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and ...

What's after Artemis II? Inside NASA's audacious plan to build a nuclear-powered moon base.

The end of the historic Artemis II mission kicks off a race to establish a permanent human presence on the moon.

NBA Draft Scouting Report: Illinois Guard Keaton Wagler

Evalauting breakout Illinois guard Keaton Wagler.

Create simple UX for domain-specific languages with VS Code

Generic formats like JSON or XML are easier to version than forms. However, they were not originally intended to be ...

ExpreS2ion Biotech Holding AB: The Board of Directors of ExpreS2ion has resolved on a rights issue of units of approximately SEK 53 million, primarily to advance its lead ...

Hørsholm, Denmark, 7 April 2026 - The Board of Directors of ExpreS2ion Biotech Holding AB (publ) ("ExpreS2ion" or the "Company") has today, on 7 April 2026, pursuant to the authorization granted by th ...